Sequential allogeneic and autologous CAR-T-cell therapy to treat an immune-compromised leukemic patient.

CAR-T–cell therapy normally requires the patient’s own healthy T cells. An allogeneic CAR-T bridging therapy could rescue lymphopenic patients.

[1]  G. Dotti,et al.  Chimeric antigen receptor T-cells for B-cell malignancies. , 2017, Translational research : the journal of laboratory and clinical medicine.

[2]  Lung-Ji Chang,et al.  Adoptive immunotherapy for B-cell malignancies using CD19-targeted chimeric antigen receptor T-cells: A systematic review of efficacy and safety. , 2017, Current medicinal chemistry.

[3]  Lung-Ji Chang,et al.  Safety and Efficacy Evaluation of 4SCAR19 Chimeric Antigen Receptor-Modified T Cells Targeting B Cell Acute Lymphoblastic Leukemia - Three-Year Follow-up of a Multicenter Phase I/II Study , 2016 .

[4]  S. Rosenberg,et al.  Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  B. Levine,et al.  Engineered T cells: the promise and challenges of cancer immunotherapy , 2016, Nature Reviews Cancer.

[6]  G. Hill,et al.  Alloantigen presentation and graft-versus-host disease: fuel for the fire. , 2016, Blood.

[7]  M. Sadelain,et al.  Biology and clinical application of CAR T cells for B cell malignancies , 2016, International Journal of Hematology.

[8]  T. Fry,et al.  Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD. , 2016, Blood.

[9]  He Huang,et al.  Chimeric Antigen Receptor 4SCAR19-Modified T Cells in Acute Lymphoid Leukemia: a Phase II Multi-Center Clinical Trial in China , 2015 .

[10]  Lung-Ji Chang,et al.  4SCAR19 Chimeric Antigen Receptor-Modified T Cells As a Breakthrough Therapy for Highly Chemotherapy-Resistant Late-Stage B Cell Lymphoma Patients with Bulky Tumor Mass , 2015 .

[11]  A. Biondi,et al.  Donor-derived CD19-targeted T cells in allogeneic transplants , 2015, Current opinion in hematology.

[12]  T. Fry,et al.  Challenges and opportunities of allogeneic donor-derived CAR T cells , 2015, Current opinion in hematology.

[13]  Sadik H. Kassim,et al.  Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Seth M Steinberg,et al.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.

[15]  Lung-Ji Chang,et al.  STAT3 signaling contributes to the high effector activities of interleukin-15-derived dendritic cells , 2015, Immunology and cell biology.

[16]  Z. Eshhar,et al.  Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer , 2014, Expert opinion on biological therapy.

[17]  H. Heslop,et al.  Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  M. Sykes,et al.  The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia. , 2007, Blood.

[19]  Lung-Ji Chang,et al.  An effective cancer vaccine modality: lentiviral modification of dendritic cells expressing multiple cancer-specific antigens. , 2006, Vaccine.

[20]  Lung-Ji Chang,et al.  Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1 , 2005, Gene Therapy.